The Experts below are selected from a list of 270 Experts worldwide ranked by ideXlab platform
Joel Sheinfeld - One of the best experts on this subject based on the ideXlab platform.
-
retroperitoneal lymph node dissection in patients with low stage testicular cancer with Embryonal Carcinoma predominance and or lymphovascular invasion
The Journal of Urology, 2005Co-Authors: Andrew J Stephenson, George J Bosl, Dean F Bajorin, Jason Stasi, Robert J Motzer, Joel SheinfeldAbstract:ABSTRACTPurpose: The outcome after primary retroperitoneal lymph node dissection (RPLND) was analyzed in patients with clinical stage I-IIA nonseminomatous germ cell testicular cancer with Embryonal Carcinoma predominance (ECP) or lymphovascular invasion (LVI).Materials and Methods: Between 1989 and 2002, 267 patients with clinical stage I-IIA nonseminomatous germ cell testicular cancer, and ECP and/or LVI underwent RPLND. Patient information was obtained from a prospective database. Median followup was 53 months.Results: Overall 42% of patients had pathological stage (PS) II disease, of whom 54% had low volume (PN1) disease and 16% had retroperitoneal teratoma. The 5-year progression-free probability was 90% overall, 90% for PS I and 86% for PN1. All patients with relapse were continuously free of disease following standard chemotherapy with or without resection of residual masses and the 10-year actuarial overall survival was 100%. When adjuvant chemotherapy was restricted to patients with PN2 disease, ...
-
results of retroperitoneal lymph node dissection for clinical stage i and ii pure Embryonal Carcinoma of the testis
The Journal of Urology, 2003Co-Authors: Kamal S Pohar, George J Bosl, Dean F Bajorin, Robert J Motzer, Farhang Rabbani, Joel SheinfeldAbstract:ABSTRACTPurpose: We determined the pathological findings and clinical outcome of patients with pure Embryonal Carcinoma (EC) of the testis managed by primary retroperitoneal lymph node dissection.Materials and Methods: From January 1989 to February 1998, 45 patients with pure EC underwent primary retroperitoneal lymph node dissection at our institution. Patients presented as clinical stage I in 26, IIA in 17 and IIB in 2. Lymphovascular invasion was present in 29 (64%). Median followup was 36.8 months.Results: Overall the pathological stage was pN0 in 11, pN1 in 10 (4 with microscopic disease) and pN2/N3 in 24 patients (8 with extranodal extension). Nineteen of 26 patients (73%) with clinical stage I and 13 of 17 (77%) patients with clinical stage IIA had retroperitoneal disease. No patient with negative lymph nodes (pN0) has had relapse. Only 1 of 9 (11%) patients with pN1 treated without adjuvant chemotherapy has had relapse. Of 24 patients with pN2/N3 disease only 3 (12%) have required more than 2 cycl...
William C Dewolf - One of the best experts on this subject based on the ideXlab platform.
-
the tra 1 60 and tra 1 81 human pluripotent stem cell markers are expressed on podocalyxin in Embryonal Carcinoma
Stem Cells, 2007Co-Authors: William M Schopperle, William C DewolfAbstract:We have previously identified the cell adhesion protein podocalyxin expressed in a human pluripotent stem cell, Embryonal Carcinoma (EC), which is a malignant germ cell. Podocalyxin is a heavily glycosylated membrane protein with amino acid sequence homology to the hematopoietic stem cell marker CD34. Since the initial discovery of podocalyxin in a cancerous stem cell, numerous new studies have identified podocalyxin in many different human cancers and in embryonic stem cells lines (ES) derived from human embryos. Embryonal Carcinoma, as do all human pluripotent stem cells, expresses TRA-1-60 and TRA-1-81 antigens, and although their molecular identities are unknown, they are commonly used as markers of undifferentiated pluripotent human stem cells. We report here that purified podocalyxin from Embryonal Carcinoma has binding activity with the TRA-1-60 and TRA-1-81 antibodies. Embryonal Carcinoma cells treated with retinoic acid undergo differentiation and lose the TRA-1-60/TRA-1-81 markers from their plasma membrane surface. We show that podocalyxin is modified in the retinoic acid-treated cells and has an apparent molecular mass of 170 kDa on protein blots as compared with the apparent 200-kDa molecular weight form of podocalyxin expressed in untreated cells. Furthermore, the modified form of podocalyxin no longer reacts with the TRA-1-60/TRA-1-81 antibodies. Thus, Embryonal Carcinoma expresses two distinct forms of podocalyxin, and the larger version is a molecular carrier of the human stem cell-defining antigens TRA-1-60 and TRA-1-81.
-
human Embryonal Carcinoma tumor antigen gp200 gctm 2 is podocalyxin
Biochemical and Biophysical Research Communications, 2003Co-Authors: Michael W Schopperle, David B Kershaw, William C DewolfAbstract:We previously characterized a peanut agglutinin-binding tumor antigen, gp200, a surface membrane glycoprotein expressed on human Embryonal Carcinoma, a malignant stem cell of testicular tumors. Gp200 is remarkably similar to another Embryonal Carcinoma antigen, GCTM-2, a cell differentiation marker that is also detected in blood of testis cancer patients, yet neither molecular identity is known. We now report the identity of gp200 as podocalyxin. Protein sequence results of gp200 peptides match with podocalyxin sequence. Furthermore, two distinct monoclonal antibodies, specific for podocalyxin, react positively with gp200. Therefore, gp200 is a testicular tumor form of podocalyxin, a surface membrane glycoprotein that was originally discovered as a scaffolding extracellular matrix protein of kidney podocyte cells. Podocalyxin is also expressed on subsets of hematopoietic cells where it has a putative function as a cell adhesion protein. This is the first report of podocalyxin expression on malignant cells.
George J Bosl - One of the best experts on this subject based on the ideXlab platform.
-
retroperitoneal lymph node dissection in patients with low stage testicular cancer with Embryonal Carcinoma predominance and or lymphovascular invasion
The Journal of Urology, 2005Co-Authors: Andrew J Stephenson, George J Bosl, Dean F Bajorin, Jason Stasi, Robert J Motzer, Joel SheinfeldAbstract:ABSTRACTPurpose: The outcome after primary retroperitoneal lymph node dissection (RPLND) was analyzed in patients with clinical stage I-IIA nonseminomatous germ cell testicular cancer with Embryonal Carcinoma predominance (ECP) or lymphovascular invasion (LVI).Materials and Methods: Between 1989 and 2002, 267 patients with clinical stage I-IIA nonseminomatous germ cell testicular cancer, and ECP and/or LVI underwent RPLND. Patient information was obtained from a prospective database. Median followup was 53 months.Results: Overall 42% of patients had pathological stage (PS) II disease, of whom 54% had low volume (PN1) disease and 16% had retroperitoneal teratoma. The 5-year progression-free probability was 90% overall, 90% for PS I and 86% for PN1. All patients with relapse were continuously free of disease following standard chemotherapy with or without resection of residual masses and the 10-year actuarial overall survival was 100%. When adjuvant chemotherapy was restricted to patients with PN2 disease, ...
-
results of retroperitoneal lymph node dissection for clinical stage i and ii pure Embryonal Carcinoma of the testis
The Journal of Urology, 2003Co-Authors: Kamal S Pohar, George J Bosl, Dean F Bajorin, Robert J Motzer, Farhang Rabbani, Joel SheinfeldAbstract:ABSTRACTPurpose: We determined the pathological findings and clinical outcome of patients with pure Embryonal Carcinoma (EC) of the testis managed by primary retroperitoneal lymph node dissection.Materials and Methods: From January 1989 to February 1998, 45 patients with pure EC underwent primary retroperitoneal lymph node dissection at our institution. Patients presented as clinical stage I in 26, IIA in 17 and IIB in 2. Lymphovascular invasion was present in 29 (64%). Median followup was 36.8 months.Results: Overall the pathological stage was pN0 in 11, pN1 in 10 (4 with microscopic disease) and pN2/N3 in 24 patients (8 with extranodal extension). Nineteen of 26 patients (73%) with clinical stage I and 13 of 17 (77%) patients with clinical stage IIA had retroperitoneal disease. No patient with negative lymph nodes (pN0) has had relapse. Only 1 of 9 (11%) patients with pN1 treated without adjuvant chemotherapy has had relapse. Of 24 patients with pN2/N3 disease only 3 (12%) have required more than 2 cycl...
Dean F Bajorin - One of the best experts on this subject based on the ideXlab platform.
-
retroperitoneal lymph node dissection in patients with low stage testicular cancer with Embryonal Carcinoma predominance and or lymphovascular invasion
The Journal of Urology, 2005Co-Authors: Andrew J Stephenson, George J Bosl, Dean F Bajorin, Jason Stasi, Robert J Motzer, Joel SheinfeldAbstract:ABSTRACTPurpose: The outcome after primary retroperitoneal lymph node dissection (RPLND) was analyzed in patients with clinical stage I-IIA nonseminomatous germ cell testicular cancer with Embryonal Carcinoma predominance (ECP) or lymphovascular invasion (LVI).Materials and Methods: Between 1989 and 2002, 267 patients with clinical stage I-IIA nonseminomatous germ cell testicular cancer, and ECP and/or LVI underwent RPLND. Patient information was obtained from a prospective database. Median followup was 53 months.Results: Overall 42% of patients had pathological stage (PS) II disease, of whom 54% had low volume (PN1) disease and 16% had retroperitoneal teratoma. The 5-year progression-free probability was 90% overall, 90% for PS I and 86% for PN1. All patients with relapse were continuously free of disease following standard chemotherapy with or without resection of residual masses and the 10-year actuarial overall survival was 100%. When adjuvant chemotherapy was restricted to patients with PN2 disease, ...
-
results of retroperitoneal lymph node dissection for clinical stage i and ii pure Embryonal Carcinoma of the testis
The Journal of Urology, 2003Co-Authors: Kamal S Pohar, George J Bosl, Dean F Bajorin, Robert J Motzer, Farhang Rabbani, Joel SheinfeldAbstract:ABSTRACTPurpose: We determined the pathological findings and clinical outcome of patients with pure Embryonal Carcinoma (EC) of the testis managed by primary retroperitoneal lymph node dissection.Materials and Methods: From January 1989 to February 1998, 45 patients with pure EC underwent primary retroperitoneal lymph node dissection at our institution. Patients presented as clinical stage I in 26, IIA in 17 and IIB in 2. Lymphovascular invasion was present in 29 (64%). Median followup was 36.8 months.Results: Overall the pathological stage was pN0 in 11, pN1 in 10 (4 with microscopic disease) and pN2/N3 in 24 patients (8 with extranodal extension). Nineteen of 26 patients (73%) with clinical stage I and 13 of 17 (77%) patients with clinical stage IIA had retroperitoneal disease. No patient with negative lymph nodes (pN0) has had relapse. Only 1 of 9 (11%) patients with pN1 treated without adjuvant chemotherapy has had relapse. Of 24 patients with pN2/N3 disease only 3 (12%) have required more than 2 cycl...
Robert J Motzer - One of the best experts on this subject based on the ideXlab platform.
-
retroperitoneal lymph node dissection in patients with low stage testicular cancer with Embryonal Carcinoma predominance and or lymphovascular invasion
The Journal of Urology, 2005Co-Authors: Andrew J Stephenson, George J Bosl, Dean F Bajorin, Jason Stasi, Robert J Motzer, Joel SheinfeldAbstract:ABSTRACTPurpose: The outcome after primary retroperitoneal lymph node dissection (RPLND) was analyzed in patients with clinical stage I-IIA nonseminomatous germ cell testicular cancer with Embryonal Carcinoma predominance (ECP) or lymphovascular invasion (LVI).Materials and Methods: Between 1989 and 2002, 267 patients with clinical stage I-IIA nonseminomatous germ cell testicular cancer, and ECP and/or LVI underwent RPLND. Patient information was obtained from a prospective database. Median followup was 53 months.Results: Overall 42% of patients had pathological stage (PS) II disease, of whom 54% had low volume (PN1) disease and 16% had retroperitoneal teratoma. The 5-year progression-free probability was 90% overall, 90% for PS I and 86% for PN1. All patients with relapse were continuously free of disease following standard chemotherapy with or without resection of residual masses and the 10-year actuarial overall survival was 100%. When adjuvant chemotherapy was restricted to patients with PN2 disease, ...
-
results of retroperitoneal lymph node dissection for clinical stage i and ii pure Embryonal Carcinoma of the testis
The Journal of Urology, 2003Co-Authors: Kamal S Pohar, George J Bosl, Dean F Bajorin, Robert J Motzer, Farhang Rabbani, Joel SheinfeldAbstract:ABSTRACTPurpose: We determined the pathological findings and clinical outcome of patients with pure Embryonal Carcinoma (EC) of the testis managed by primary retroperitoneal lymph node dissection.Materials and Methods: From January 1989 to February 1998, 45 patients with pure EC underwent primary retroperitoneal lymph node dissection at our institution. Patients presented as clinical stage I in 26, IIA in 17 and IIB in 2. Lymphovascular invasion was present in 29 (64%). Median followup was 36.8 months.Results: Overall the pathological stage was pN0 in 11, pN1 in 10 (4 with microscopic disease) and pN2/N3 in 24 patients (8 with extranodal extension). Nineteen of 26 patients (73%) with clinical stage I and 13 of 17 (77%) patients with clinical stage IIA had retroperitoneal disease. No patient with negative lymph nodes (pN0) has had relapse. Only 1 of 9 (11%) patients with pN1 treated without adjuvant chemotherapy has had relapse. Of 24 patients with pN2/N3 disease only 3 (12%) have required more than 2 cycl...